1. Health

Discuss in my forum

Carol Eustice

Tofacitinib for Rheumatoid Arthritis Produces Promising Trial Results

By March 6, 2011

Follow me on:

Tofacitinib is a rheumatoid arthritis drug which is being developed by Pfizer. The drug, which is in the second of six late-stage clinical trials, has reportedly shown that it reduces signs and symptoms of rheumatoid arthritis by a statistically significant amount when compared to placebo at 6 months. At 3 months, tofacitinib showed that it significantly improved physical function -- and also at 6 months, the drug reduced disease activity.

Tofacitinib was tested in patients with moderate to severe rheumatoid arthritis who had failed traditional treatments. Tofacitinib, previously known as tasocitinib, belongs to a new class of drugs for rheumatoid arthritis called JAK inhibitors, so named because the drug targets the protein JAK (Janus kinase). Tofacitinib is an oral therapy and it's expected to compete well against biologic injectables. Other drugmakers are also developing JAK inhibitors, but Pfizer's tofacitinib is the furthest along in the pipeline.

Related Resources:

Join the Discussion: Arthritis Forum
Follow Us: Twitter and Facebook
Sign Up: Free Arthritis Newsletter

Photo A.D.A.M.

Comments
August 13, 2012 at 2:49 pm
(1) T D says:

The hidden surprise in tofacitinib is that because it is a JAK inhibitor, it has been shown effective against two disorders caused by HTLV: HAM and ATL. There are WAY more HTLV sufferers than arthritis sufferers, so this drug will go through the roof because HTLV sufferers will simply go to their doctors and say “I have arthritis” in order to receive relief for their HAM and ATL disorders caused by HTLV.

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.